N-methyl-2-oxo-N-phenyl-1H-quinoline-3-carboxamide | 551936-80-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-methyl-2-oxo-N-phenyl-1H-quinoline-3-carboxamide
• CAS: 551936-80-2
• 化学式: C₁₇H₁₄N₂O₂
• 分子量: 278.31
• InChiKey: UZMFXHBOGLCNQI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-methyl-2-oxo-N-phenyl-1H-quinoline-3-carboxamide 、 碘甲烷 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以85.6%的产率得到N,1-二甲基-2-氧代-N-苯基喹啉-3-甲酰胺
  参考文献：
  名称：

  Structure–activity relationships studies of the anti-angiogenic activities of linomide

  摘要：

  The synthesis and anti-angiogenic activities of linomide and its analogues are reported. Three of the analogues are 3.3-69 times more potent than linomide at inhibiting blood vessel formation in the CAM angiogenesis assay. These compounds possessed considerable anti-proliferative activity against isolated HUVEC cells with no activity against epithelial-derived prostate tumor cells. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00047-7
• 作为产物：
  描述：

  2-羟基-3-喹啉羧酸 在 氯化亚砜 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-methyl-2-oxo-N-phenyl-1H-quinoline-3-carboxamide
  参考文献：
  名称：

  Structure–activity relationships studies of the anti-angiogenic activities of linomide

  摘要：

  The synthesis and anti-angiogenic activities of linomide and its analogues are reported. Three of the analogues are 3.3-69 times more potent than linomide at inhibiting blood vessel formation in the CAM angiogenesis assay. These compounds possessed considerable anti-proliferative activity against isolated HUVEC cells with no activity against epithelial-derived prostate tumor cells. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00047-7

文献信息

• [EN] PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE PYRIDONÉAMIDE EN TANT QU'INHIBITEURS DE LA KINASE D'ADHÉSION FOCALE (FAK) ET LEUR UTILISATION POUR LE TRAITEMENT DU CANCER
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009024332A1

  公开（公告）日：2009-02-26

  Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

  本发明的对象是公式(I)的化合物及其药用盐、对映体形式、二对映异构体和混合物，上述化合物的制备，含有它们的药物以及它们的制造，以及上述化合物在控制或预防癌症等疾病中的用途。
• PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2190834A1

  公开（公告）日：2010-06-02
• BIOMARKERS PREDICTIVE OF LUPUS PROGRESSION AND USES THEREOF
  申请人：Biogen MA Inc.

  公开号：EP3143399A1

  公开（公告）日：2017-03-22
• [EN] BIOMARKERS PREDICTIVE OF LUPUS PROGRESSION AND USES THEREOF<br/>[FR] BIOMARQUEURS PRÉDICTIFS DE L'ÉVOLUTION DU LUPUS ET UTILISATIONS DE CEUX-CI
  申请人：BIOGEN MA INC

  公开号：WO2015175424A1

  公开（公告）日：2015-11-19

  Methods, systems and kits to detect and/or quantify lupus and disease progression in a subject having, or at risk of having, lupus are disclosed.